Bdparp150mg

(Bdparp Olaparib) 150mg Tablet is a medication used to treat certain types of cancer. Here are some key points about the product:

Composition:

Bdparp(Olaparib) 150mg Tablet contains olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor that targets cancer cells.

Indications:

Bdparp(Olaparib) 150mg Tablet is indicated for the treatment of:

1. BRCA-mutated advanced ovarian cancer in patients who have received at least three previous chemotherapy regimens
2. BRCA-mutated metastatic breast cancer in patients who have received at least two previous chemotherapy regimens

Mechanism of Action:

Bdparp Olaparib 150mg Tablet works by:

1. Inhibiting the activity of PARP, an enzyme that helps repair DNA damage
2. Targeting cancer cells that have BRCA mutations, which impair their ability to repair DNA damage
3. Reducing the growth and proliferation of cancer cells

Dosage and Administration:

The recommended dosage of Bdparp (Olaparib) 150mg Tablet is:

• 150mg taken orally twice daily, with or without food
• Take at the same time each day

Side Effects:

Common side effects of Bdparp (Olaparib) 150mg Tablet include:

1. Fatigue
2. Nausea
3. Vomiting
4. Diarrhea
5. Abdominal pain
6. Rash

Serious side effects can include:

1. Myelodysplastic syndrome (MDS)
2. Acute myeloid leukemia (AML)
3. Hepatotoxicity (e.g., liver damage)
4. Hematological toxicity (e.g., anemia, thrombocytopenia)

Contraindications:

Bdparp(Olaparib) 150mg Tablet is contraindicated in patients with:

1. Hypersensitivity to olaparib
2. Pregnancy or breastfeeding
3. Severe hepatic impairment (Child-Pugh C)

Precautions:

1. Patients with a history of liver disease or liver damage should be closely monitored while receiving Bdparp (Olaparib) 150mg Tablet.
2. Patients with a history of hematological disorders or blood dyscrasias should be closely monitored while receiving Bdparp  (Olaparib) 150mg Tablet.

Patient Counseling:

• Patients should be counseled on the importance of taking their medication as directed and not missing doses.
• Patients should be instructed to report any signs of fatigue, nausea, or abdominal pain.
• Patients should be advised to report any changes in their menstrual cycle or symptoms of bone loss.

Storage and Handling:

• Store bottles at room temperature between 15°C and 30°C (59°F and 86°F).
• Do not expose to direct sunlight or moisture.
• Use within 24 hours of opening.

Please note that the dosage and administration information is based on the recommended dosage and may vary depending on individual patient needs and circumstances.